Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China.
J Hematol Oncol. 2017 May 17;10(1):110. doi: 10.1186/s13045-017-0479-y.
Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. These assays use a variety of detection platforms at different levels (protein, mRNA), employ diverse biopsy and surgical samples, and have disparate positivity cutoff points and scoring systems, all of which complicate the standardization of clinical decision-making. This review summarizes the current understanding and ongoing investigations regarding PD-L1 expression as a potential biomarker for clinical outcomes of anti-PD-1/PD-L1 immunotherapy.
程序性死亡配体 1（PD-L1）已成为一种生物标志物，可以帮助预测针对 PD-L1 及其受体（PD-1）的免疫疗法的反应。已经为许多癌症免疫治疗药物开发了评估 PD-L1 表达作为反应生物标志物的伴随检测。这些检测使用不同水平（蛋白质、mRNA）的各种检测平台，采用不同的活检和手术样本，具有不同的阳性截止点和评分系统，所有这些都使临床决策的标准化变得复杂。本综述总结了目前对 PD-L1 表达作为抗 PD-1/PD-L1 免疫治疗临床结局的潜在生物标志物的理解和正在进行的研究。
